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Background: Medication can ease symptoms and limit disease progression in rheumatoid 
arthritis (RA). Despite this, nonadherence to medication is common in RA. We explored the 
determinants of high and low adherence to disease-modifying antirheumatic drugs (DMARDs) in 
patients with RA and provide suggestions on approaches to improving adherence to DMARDs.
Methods: Patients with RA were identified from those who had previously participated in 
a questionnaire measuring levels of medication adherence. Twenty patients participated (ten 
high and ten low adherers, as determined by responses to the Medication Adherence Report 
Scale). In-depth individual semistructured interviews were undertaken until data satura-
tion was reached. Interviews were transcribed and analyzed using a constant comparative 
method.
Results: Four main themes related to adherence were identified: 1) symptom severity; 2) ill-
ness perception; 3) perceived benefits and risks of DMARDs; and 4) the quality and quantity 
of information about RA and DMARDs. In addition, patients’ suggestions about strategies 
to optimize adherence to DMARDs were captured and they fell within the following themes: 
1) musculoskeletal ultrasound to explain the disease process and to provide objective feed-
back about the extent to which their disease activity is being effectively controlled; 2) better 
explanations of the consequences of poorly controlled RA; and 3) a good relationship with the 
health professional.
Conclusion: Patients’ beliefs about medicines, perceptions about RA, and level of satisfac-
tion with information about DMARDs influenced their adherence to DMARDs. The use of 
musculoskeletal ultrasound to image the inflamed joint may help to improve patient adherence 
to DMARDs.
Keywords: rheumatoid arthritis, medication adherence, patients’ suggestion to improve 
medication, disease-modifying antirheumatic drugs
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by 
synovitis and associated with joint destruction.1 RA causes progressive decline in 
functional ability and limits participation in social and work-related activities.2 RA 
is also associated with an increased risk of extra-articular complications including 
ischemic heart disease.3 While curative therapies are not currently available, treat-
ments with disease-modifying antirheumatic drugs (DMARDs) and biologic agents 
improve joint function,1 work productivity,4 and health-related quality of life, reducing 
correspondence: Kanta Kumar
Primary care clinical sciences, 
University of Birmingham, Vincent Drive, 
Birmingham B15 2TT, UK
email k.kumar@bham.ac.uk
Journal name: Patient Preference and Adherence
Article Designation: Original Research
Year: 2016
Volume: 10
Running head verso: Kumar et al
Running head recto: Medication adherence in RA patients
DOI: http://dx.doi.org/10.2147/PPA.S99702





the risk of joint destruction, disability, and morbidity and 
improving the life expectancy.5 Despite these treatments, 
many patients fail to achieve optimal disease control, in part, 
due to nonadherence.6
The World Health Organization defines adherence 
as “the extent to which the patient’s behavior coincides 
with the health professional’s advice”.7 Nonadherence to 
medication remains a major problem across the spectrum of 
chronic diseases.8,9 Factors associated with poor medication 
adherence are complex.7 In RA, only a small proportion 
of the variance in adherence is explained by demographic 
characteristics which are largely unchangeable,10 therefore 
necessitating the identification of other modifiable factors 
that could be changed.11,12 It is widely reported that patients’ 
beliefs about medicines can have a major impact on their 
decision to take them.13–15
Medication-taking behavior might be enhanced by a 
better understanding of the types of belief that are associ-
ated with poor adherence.16 This understanding can be 
obtained by employing the Necessity–Concerns Framework 
(NCF)16 and the Self-Regulatory Model (SRM)-Common 
Sense Model (CSM).17 The SRM-CSM/NCF framework 
allows researchers to see how adherence is associated 
with the ways in which patients judge their personal need 
for their prescribed medicines relative to their concerns 
about possible side effects.11,15 Studies across long-term 
conditions including RA have demonstrated the utility of 
the SRM-CSM/NCF with nonadherence related to doubts 
about personal need for treatment and concerns about side 
effects.11,15 Patients’ judgment about prescribed medications 
may be influenced by more general attitudes to medicines 
as a whole, for example, perceptions that medicines are 
harmful, addictive, and poisonous and are overused by 
doctors.18 Negative attitudes and beliefs about DMARDs 
appear more prevalent within certain ethnic groups includ-
ing the South Asian population where many patients have 
negative attitudes toward DMARDs.19 However, those stud-
ies that report data on the impact of beliefs about medicines 
on adherence have not included South Asian patients with 
RA.13–15,20 Health care professionals managing patients with 
RA need to understand the influence of health beliefs on 
medication adherence, as nonadherence is costly.10 As part 
of a questionnaire study examining determinants of medica-
tion adherence in patients of White British and South Asian 
origin,21 we explored the views about DMARDs and the 
determinants which influence medicine-taking by patients 
with RA. In addition, we documented patients’ suggestions 
about adherence-enhancing strategies.
Materials and methods
Ethical approval for this study was granted by the South 
Birmingham Research Ethics Committee, and all patients 
gave written informed consent.
The study took place at Sandwell and West Birmingham 
Hospitals NHS Trust and University Hospitals Birmingham 
NHS Foundation Trust, UK. Patients were selected from 
those who had participated in a previous questionnaire study 
of 180 patients with RA.21 Patients in that cross-sectional 
study had had a diagnosis of RA (according to the 1987 
American College of Rheumatology criteria)22 for at least 
3 months, were aged 18 and over, and were taking at least 
one DMARD or had taken a DMARD in the past.
Patients were selected purposively to ensure a mix-
ture of age, sex, language spoken, and employment status 
(Table 1).21
All 180 patients who had taken part in the questionnaire 
study were given a questionnaire (Medication Adherence Rate 
Score)15 that measured self-reported medication adherence. 
“High” adherence was defined as a Medication Adherence 
Rate Score15 in the upper tertile (Table 1) and “low” adher-
ence as a score in the lowest tertile. Patients in the middle 
tertile were excluded. There were 50 high-adhering patients 
(White British 33, South Asian 17) and 62 low-adhering 
patients (White British 23, South Asian 39); and from these 
112 patients, 36 were invited by mail for an interview. Patients 
who responded to letters were recruited into the study (high 
adherers: ten White British, eight South Asians; low adherers: 
six White British, 12 South Asians); 16 declined.
Table 1 Demographic data of the patients interviewed













Off work due to rA 2 1
Notes: High adherence defined as a MARS of $25 (ie, in the upper tertile 
of responses) and low adherence as a MArs of #25 (ie, in the lower tertile of 
responses). *$25 is the maximum possible score of MArs and 18 was the lowest 
observed score of MArs in our cross-sectional study.
Abbreviations: MArs, Medication Adherence rate score; rA, rheumatoid 
arthritis.




Medication adherence in rA patients
A group of Patient Research Partners were part of the 
steering committee that helped with the development of 
the topic prompt (Figure 1). The topic guide was organized 
around questions broadly based on the NCF, SRM,14 and 
patient satisfaction with information about DMARDs. Initial 
questions were general (eg, “What do you think about your 
DMARDs?”), and were followed by prompts based on the 
NCF (eg, “How necessary do you feel the DMARD(s) is for 
you?” and “Do you have any concerns about DMARDs?”). 
In addition, questions were asked about the patients’ adher-
ence or nonadherence to DMARDs, including stopping and 
changing the doses of DMARDs and reasons for doing so. 
Patients’ recommendations as to how adherence could be 
improved were also elicited.
Individual interviews with patients were conducted at 
two hospitals in areas designated for research, away from 
their routine clinical setting. The interviews were undertaken 
by KK who was fluent in both English and Punjabi. Five 
patients chose to be interviewed in Punjabi. Recruitment 
and interviewing continued until data saturation had been 
reached in both groups.
Each interview lasted approximately 1 hour. All 
interviews were audio-taped and transcribed verbatim 
by KK. A selection of English transcriptions was inde-
pendently checked for emerging themes by KK, PG, and 
SG. A sample of the English-translated transcripts from 
Punjabi-speaking patients was validated for accuracy by 
an independent health professional (AJ). Any discrepan-
cies regarding themes were discussed and agreed. The 
overall analysis was organized by labeling data relevant23 
to each of the questions in the topic guide and then group-
ing similar themes.24 Constant comparison25 was used to 
analyze the transcripts line by line, comparing the themes 
related to high- and low-adhering patients’ views about 
DMARDs.25 Particular emphasis was placed on comparing 
determinants influencing medicine-taking that differed 
between ethnic groups. Data on strategies that were rec-
ommended by high-adhering patients to help improve the 
area of medication adherence for patients with RA were 
identified.
Results
Twenty interviews were conducted (with ten high-adhering 
patients and ten low-adhering patients). Fourteen participants 
were female and eight were in full-time employment. Fifteen 
were interviewed in English and five in Punjabi. Four themes 
related to adherence were identified in both high- and low-
adhering patients: 1) symptom severity; 2) illness perception; 
3) perceived benefits and risks of DMARDs; and 4) the qual-
ity and quantity of information about RA, DMARDs, and the 
need for DMARDs. In addition, patients’ suggestions about 
strategies to optimize adherence to DMARDs were captured 
(Table 2) and they fell within the following themes: 1) visual 
representations to explain the disease process and to provide 
objective feedback about the extent to which their disease 
activity is being effectively controlled; 2) better explanations 
of the consequences of poorly controlled RA; 3) a good rela-
tionship with the health professional; and 4) access to patient 
support groups. Each theme is illustrated with quotations 
from the transcripts. The data from high-adhering patients 
are presented first.
Results from patients with high 
adherence
symptom severity
Seven patients perceived RA medication to be very impor-
tant; this was related to patients’ current experience of symp-
toms and their recollection of severe symptoms at disease 
onset (Quote 1). They were also aware that uncontrolled 
RA could lead to future health problems (Quote 2). As a 
result of both symptom severity and awareness of future 
risks, the high-adhering patients viewed RA medicines to 
•	 What do you think about your medications (DMARDs) that you take for controlling your RA?
• How necessary do you feel the medication (name of DMARD) is for you? (Prompts: do you stop them, how long, would there be a 
reason for stopping DMARD?)
• Do you feel that these are working to control your symptoms? (Prompt: do you change the doses?)
• Do you have any concerns about the DMARDs?
• Tell me about RA. Do you view this to be a short-term disease or lasting for a long time? (Prompt: do you think DMARD will control 
your RA?)
• Have you had enough information about your condition and the DMARD?
• How can we improve the area of medicine-taking? What can be done to help patients understand the DMARDs we give? (Themes 
that arose from the high-adhering patients were introduced to the low-adhering patients.)
Figure 1 Topic guide based on srM-csM and ncF (questions asked during the interviews).
Abbreviations: csM, common sense Model; DMArDs, disease-modifying antirheumatic drugs; ncF, necessity–concerns Framework; rA, rheumatoid arthritis; srM, 
self-regulatory Model.





be important. Family history of RA appeared to increase the 
level of importance in four of the patients. (Quote 3).
Quote 1: I will take this medication for the rest of my life. 
I wouldn’t stop taking them just to test it out. I just don’t 
want to go where I was. [59, retired, English speaking, 
White patient]
Quote 2: I have no doubt in my mind that if I stop taking 
these medications then I know that I would be in a wheel-
chair. [34, nurse, English speaking, Asian patient]
Quote 3: I have had experience of my mother. She had 
exactly the same problem as me. She really suffered. I saw 
her disease develop over time. That really put the fright in 
me. [34, nurse, English speaking, Asian patient]
illness perception
Regarding patients’ views about RA, all ten high-adhering 
patients identified a range of factors that they felt had 
caused their RA, but none believed that the disease was a 
transient illness or was curable. They all accepted the need 
for long-term therapy (Quote 4) and held the belief that 
taking DMARDs regularly would help to control the disease 
(Quotes 5 and 6).
Quote 4: I doubt it very much that it can be cured yes it 
can be controlled. [62, retired, English speaking, White 
patient]
Quote 5: When I went to my first appointment with the 
nurse and the way she was talking it seemed I would be on 
methotrexate for very long time don’t know … may be even 
for the rest of life because there isn’t a cure for this is there? 
[52, retired, English speaking, White patient]
Quote 6: I have watched my cousin with this arthritis after 
twenty years he still has it you know … so I know it’s not 
going to go away. [51, off work due to RA, English speak-
ing, Asian patient]
Perceived benefits and risks of DMARDs
Nine patients described their DMARD(s) as working to 
control their RA. Patients made decisions by weighing up the 
benefits and concerns and/or perceptions about the efficacy 
of treatment. For example, those who were taking anti-tumor 
necrosis factor (TNF) therapy (six patients) believed that 
their lives had been transformed through taking this class 
of drug and that it was more effective in controlling their 
symptoms than their previous nonbiologic DMARDs. This 
view emerged from both White British and South Asian 
patients (Quotes 7 and 8). The patients who viewed their 
medicines as necessary (all ten patients) expressed fewer 
concerns about medicines and did not question the necessity 
of DMARDs (Quote 9). This appraisal was based on the 
theme related to symptom severity and views about control 
rather than cure. Five patients gave examples of their past 
experiences of stopping medication and how the decision to 
discontinue DMARDs for a while had led to disease flares 
(Quotes 10 and 11). The remaining five gave examples of 
the persistent presence of RA symptoms. These evaluations 
helped to form beliefs about the necessity of DMARDs 
Table 2 comparison of themes and subthemes by adherence level
Themes High adherers Low adherers 
symptom severity •	 severe symptoms
•	 Family history of rA
•	 Mild symptoms
illness perception •	 Patients accept that there is no cure for rA
•	 Patients accept that rA is a long-term disease
•	 Patients seek for a cure of rA through their  
treatment
•	 Patients perceive rA to be a short-term disease
Perceived benefits and  
risks of DMArDs
•	 Patients’ beliefs about the necessity of DMArDs 
outweigh their concerns
•	 Patients’ experiences of the beneficial effects  
of DMArDs in controlling disease activity
•	 Patients’ concerns about DMArDs outweigh  
their beliefs about the necessity of DMArDs
The quality and  
quantity of information
•	 satisfaction with information/visual aids
•	 good relationship with health professionals
•	 good knowledge about disease parameters
•	 lack of information, no experience of visual aids
•	 Poor relationship with health professionals
•	 Poor knowledge about disease parameters
Patients’ suggestions  
about strategies to  
optimize adherence  
to DMArDs
•	 Visual representations to explain the disease process and to provide objective feedback about the extent to 
which their disease activity is being effectively controlled
•	 Better explanations of the consequences of poorly controlled rA
•	 A good relationship with the health professional
•	 Access to patient support groups
Abbreviations: DMArDs, disease-modifying antirheumatic drugs; rA, rheumatoid arthritis.
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and these patients reported that they were now completely 
adherent to DMARDs.
Quote 7: Rituximab has transformed my life now. The rheu-
matoid arthritis has kept under control since I have started 
on that. [62, retired, English speaking, White patient]
Quote 8: Initially I couldn’t even bend my knees I couldn’t 
do my household chores, since I have been on methotrex-
ate …. Yes I can do these now. I am a paediatric nurse 
and I am on my feet all the time. So for me to take the 
medicines is very important. [36, manager, English speak-
ing, Asian patient]
Quote 9: I think that sometimes you think I am taking all 
these medicines … like methotrexate they could damage 
your kidneys your liver … but I would rather have that 
danger rather than how I was before. So the dangers of 
the drugs that I hear mean nothing to me because I want 
to be how I am now. [52, house wife, English speaking, 
White patient]
Quote 10: I stopped it for a while [methotrexate] but my 
flare had come back so I knew I had to take it. [36, manager, 
English speaking, Asian patient]
Quote 11: I know this would get worse you see. It’s there 
all the time and stopping the medication will make it 
worse. [42, machine operator, English speaking, White 
patient]
A range of concerns about DMARDs appeared to be 
related to the different types of DMARDs used. For example, 
concerns about short- and long-term side effects of their cur-
rent DMARDs and their previous experiences of side effects 
were mentioned by all ten patients. Three patients expressed 
the view that taking DMARDs was like taking poison and 
viewed these drugs to be “unnatural”. One South Asian patient 
viewed methi (an Indian herb) and ginger to be more natural 
than DMARDs (Quote 12). However, despite these concerns, 
the drivers for the need for DMARDs led the patients to take 
their DMARDs as prescribed (Quote 13). Three of the patients 
expressed that DMARDs were less serious than some other 
therapies such as certain cancer treatments (Quotes 14–16) 
and this promoted adherence to DMARDs.
Quote 12: I do try and take methi (Indian herb) and ginger. 
I have fresh ginger every day to help get rid of the toxins 
(swelling in joints). [51, off work due to RA, Punjabi speak-
ing, Asian patient]
Quote 13: I really hate this medication [methotrexate]. But 
I appreciate that I need to take it I guess it’s a reasonable 
compromise. [62, retired, English speaking, White patient]
Quote 14: I thought look … there are people on cancer 
medicine where their hair falls out and I am not that bad 
to take these. [42, machine operator, English speaking, 
White patient]
Quote 15: You know, at least I haven’t got cancer its only 
arthritis. [52, house wife, English speaking, White patient]
Quote 16: I mean at least it wasn’t leukaemia or something, 
you know. I mean touch wood I mean it’s not bad as that. 
I mean it is bad but you know … cancer is a bad thing to 
have. [55, unemployed, English speaking, White patient]
Quality and quantity of information
When patients were asked about what information they found 
useful as a basis for their decisions to take DMARDs, they 
gave a range of spontaneous responses. Eight patients believed 
that seeing an ultrasound scan of one of their inflamed joints 
had helped them to understand the nature and extent of their 
disease. These patients stated that they were less likely to stop 
taking their DMARDs after having seen imaging evidence of 
synovitis (Quotes 17–20). The images also helped patients 
to understand the seriousness of the condition (Quote 21). 
Two patients made reference to ultrasound scans and plain 
radiographs as having helped them not only to understand the 
nature of the disease but also to accept the condition.
Quote 17: Dr XX scanned my joints and he showed me my 
joints and that helped me understand what was going on in my 
joints. He explained what was happening … there were differ-
ent lights flashing and red was showing swelling in the joints. 
[42, machine operator, English speaking, White patient]
Quote 18: The scan pictures really helped me to understand 
the disease and to be honest this really motivates me to take 
the methotrexate. You see I know why I have got to do it. 
[36, manager, English speaking, Asian patient]
Quote 19: The scan showed me the lights flashing on my 
joint swelling. It made me scared and helped me to know 
how serious the condition can be. [51, off work due to RA, 
Punjabi speaking, Asian patient]
Quote 20: … but when she showed me the X-rays I under-
stood the reasons for my pain and also saw the damage that 
the disease had caused. [55, unemployed, English speaking, 
White patient]





Quote 21: When I saw the X-rays and the damage I thought 
you know … I need to listen to what is being said and accept 
this is for life. So I am taking my medication and slowly 
here I am today not that bad. [34, nurse, English speaking, 
Asian patient]
Quote 22: It really makes a difference when you can get on 
with your doctors. Mine explained the disease really well. 
[42, machine operator, English speaking, White patient]
Quote 23: Yeh I mean it makes it easier when the team sup-
port is there it makes you feel that you are not alone and 
there is support there you know. It does make the journey 
that much easier otherwise you get lost and we take so many 
medicines. [36, manager, English speaking, Asian patient]
For some patients (six patients), changes in the measured 
disease activity parameters (blood tests, disease activity score) 
produced a positive effect in terms of accepting the need for 
continuous DMARDs. For others (four patients), a positive 
view about taking DMARDs was facilitated by a good rela-
tionship with health professionals and an in-depth explanation 
of the nature of the disease (Quote 22), in particular RA sever-
ity and long-term consequences and explanations about the 
treatment options available (Quote 23). Information leaflets 
and use of the Internet were also identified as useful sources 
of information (four patients), though others (six patients) 
stated that the leaflets on RA that they had been given did not 
effectively communicate the seriousness of the disease and 
were not helpful in visualizing how untreated synovitis could 
damage joints. Good explanations regarding the seriousness 
of the disease, ultrasound scans of joints, support by health 
professionals, and a good explanation of the fluctuating nature 
of the disease all acted as factors that motivated patients to 
begin and continue to take DMARDs.
Results from patients with low 
adherence
symptom severity
Some low-adhering patients had similar experiences to 
high-adhering patients regarding their symptom severity 
(Quote 24). However, there were five patients (all South 
Asian) in whom symptom experiences were mild (patient’s 
view) at the beginning and as the treatment gave them relief, 
their reaction was to stop the medication as they thought that 
the disease had been cured (Quote 25).
Quote 24: I was in so much pain and I thought gosh I 
would die rather than staying in bed like that … it was bad. 
[44, microbiologist, English speaking, Asian patient]
Quote 25: When I started on methotrexate I was well for 
about five years. Because I was well for so many years 
and I didn’t really have any pain I made myself believe 
that the disease has cured. [69, retired, Punjabi speaking, 
Asian patient]
illness perception
In contrast to high-adhering patients, some of the low-
adhering patients held the view that the disease was curable 
and saw medication as a short-term therapy. This was par-
ticularly the case among the South Asian patients (Quotes 26 
and 27). Furthermore, their decisions to take medication were 
based on their perception of RA (Quotes 28 and 29). One 
South Asian patient had stopped methotrexate to try herbal 
treatment instead.
Quote 26: For a year I really battled with myself. Even 
to now this day I believe that the disease can be cured … 
it will get better. [33, self-employed, English speaking, 
Asian patient]
Quote 27: I have been taking them for a year and now 
you would think that this could be cured … but it hasn’t. 
[69, retired, Punjabi speaking, Asian patient]
Quote 28: To be honest I thought I am 33 so maybe I am 
getting old or something. I mean this is only old person 
disease right … I mean, for arthritis, people live with it 
they don’t take long-term medicines. [33, self-employed, 
English speaking, Asian patient]
Quote 29: You see I never heard of arthritis well, I didn’t 
think it would be in a young person like me. So I thought at 
the time I would be on paracetamol and it would go away. 
[61, housewife, Punjabi speaking, Asian patient]
Perceived benefits and risks of DMARDs
Although the low-adhering patients viewed DMARDs as 
necessary and agreed that these medications were helpful in 
maintaining their function, they also had concerns. In South 
Asian patients, fears about dependency led them either to 
miss doses or to stop treatment temporarily (Quotes 30 
and 31). The increased concern about side effects and depen-
dency was partly linked to limited knowledge of the disease; 
again, this was mainly noted in South Asian patients. Some 
South Asian patients believed that the long-term usage of 
DMARDs could lead to additional physiological abnormali-
ties (Quote 32). Three patients stated that medicines were 
poisonous (Quote 33). Two White British low-adhering 
patients viewed biologic agents such as anti-TNF to be 
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important, but stated that they often missed doses of their 
nonbiologic DMARDs (Quotes 34 and 35).
Quote 30: I don’t like taking them (methotrexate) like the 
biggest thing for me is the hair loss you know. [44, micro-
biologist, English speaking, Asian patient]
Quote 31: I know that if I take these everyday then I am 
dependant on them for the rest of my life. [37, legal secre-
tary, English speaking, Asian patient]
Quote 32: I read that these tablets can give you gastric 
problems. Then you have to take more tablets it’s a never 
stopping process. [41, off work due to RA, Punjabi speak-
ing, Asian patient]
Quote 33: You see these are not natural. I know I have to 
take them but they are poisons. When I don’t need them 
I stop them for a while. [61, house wife, Punjabi speaking, 
Asian patient]
Quote 34: I am on Humira and this keeps my disease under 
control. I don’t think I should keep taking my methotrex-
ate when I am controlled more on this drug [Humira]. 
[41, social worker, English speaking, White patient]
Quote 35: I will be honest with you … since I have been 
on these injections [anti-TNF therapy] I really think back 
why was I even taking these other ones [sulphasalazine]. 
[63, retired, English speaking, White patient]
Quality and quantity of information
The reasons for low adherence to DMARDs were linked to 
a lack of understanding about RA in six patients (Quotes 36 
and 37); this was particularly noted among the South Asian 
patients. The majority of South Asian patients attributed 
their poor adherence to DMARDs, in part, to the fact that 
they felt that RA was not generally well known or taken 
seriously within the South Asian community (Quote 2). 
Five South Asian patients held the view that arthritis was a 
disease of the elderly and they did not understand the need 
for long-term therapy. Furthermore, the South Asian patients 
had very little understanding of the fluctuating pattern of the 
disease (Quote 38). Patients expected more information from 
their health professionals and felt that they were not always 
as aware of disease parameters as they would like to be 
(Quote 39). When asked whether they had experienced having 
an ultrasound scan of the joints, none of the patients in the low-
adhering group had been exposed to this test (Quote 40).
Quote 36: Who cares if I have rheumatoid arthritis? 
Everyone has joint pains and this what people generally 
think. [69, retired, Punjabi speaking, Asian patient]
Quote 37: I still believe that this disease is not holding the 
same awareness as the heart diseases … so people don’t 
take arthritis seriously … err the medication is not taken 
seriously. [37, legal secretary, English speaking, Asian 
patient]
Quote 38: I didn’t know that this disease can come and go 
like this. If I had known I would not reduce my medications. 
[33, self-employed, English speaking, Asian patient]
Quote 39: No I wasn’t aware of this my doctor didn’t tell 
me [referring to disease activity measure – disease activity 
score]. So this works like a blood pressure when it is high 
you know it’s serious? [41, off work due to RA, Punjabi 
speaking, Asian patient]
Quote 40: No I didn’t ever have anything like this. [referring 
to ultrasound scan of joints] [37, legal secretary, English 
speaking, Asian patient]
Patients’ suggestions about 
strategies to optimize adherence 
to DMARDs
Themes that acted as drivers for high adherence to DMARDs 
(such as the quality and quantity of information provided) 
were suggested to low-adhering patients as potential ways 
of improving their adherence to DMARDs. All low-adhering 
patients (ten patients) agreed on the potential benefits of the 
drivers that were suggested by high-adhering patients. When 
patients with low adherence were asked about the types of 
visualization tool they felt would best improve adherence, 
they said they would prefer to see real-time ultrasound images 
rather than static images of joints that were not their own. 
However, some patients (three patients) indicated that picto-
rial representations would be better included in leaflet form. 
Seven low-adhering patients believed that the visualization 
of swelling in joints would enhance patients’ understand-
ing of the nature and severity of the disease and the need to 
take medicines in the long term (Quotes 41 and 42). All ten 
patients further added that showing them the results of other 
disease parameters such as a measure of inflammatory makers 
in the blood or composite disease activity scores would also 
encourage them to take their DMARDs as prescribed (Quote 
43). All ten patients highlighted that good communication 
with health professionals, health professional support, and 
better explanation of the risks of RA to their health would 





all promote better medication adherence (Quotes 44–46). 
Three patients felt that the level of engagement with disease 
information was an individual choice (Quote 47).
Quote 41: I think the scan would change your attitude to 
how you think about medicines …. [44, Microbiologist, 
English speaking, Asian patient]
Quote 42: You see I need something to validate to show me 
that I have a condition serious as this (rheumatoid arthritis). 
I think a scan can do this …. [37, legal secretary, English 
speaking, Asian patient]
Quote 43: My friend has a sugar monitoring machine he 
knows what a good and high level is. So if you told patients 
about disease activity levels it would encourage knowing 
how the medicines are working. [69, retired, English speak-
ing, White patient]
Quote 44: Knowing how this disease will affect us in the 
future needs to be explained … so the seriousness of the 
disease does need to be told …. [56, off work due to RA, 
Punjabi speaking, Asian patient]
Quote 45: You see the disease isn’t viewed seriously, so 
if the risks aren’t explained then people will not take the 
medication seriously. [63, retired, Punjabi speaking, Asian 
patient]
Quote 46: Knowing the team is there to support you … the 
journey is shared and if the patients are made to feel like 
this then it’s easier, you know. [69, retired, English speak-
ing, White patient]
Quote 47: Hmm I am not sure on what would help …. I think 
it doesn’t matter what you use to explain the disease; it’s 
all up to the individual, isn’t it? I mean if I want to know 
more then I will, but it’s all on how I want to take this …. 
[63, retired, English speaking, White patient]
Discussion
This study has highlighted the role of symptom experi-
ence, illness perceptions, the perceived benefits and risks of 
DMARDs, and the quality and quantity of information about 
RA and DMARDs in determining adherence to DMARDs. 
The findings provide an insight into some of the drivers and 
barriers for RA patients’ behavior toward their medication. 
Decisions not to take DMARDs were driven by the perception 
that RA was a nonserious, short-term condition, having insuf-
ficient information regarding the disease and the importance 
of regular DMARD therapy, and lack of discussion around 
disease parameters (eg, blood-based inflammatory marker 
results and disease activity scores). The high-adhering 
patients based their decision to take DMARDs on the per-
ception that RA was a serious and long-term disease and felt 
that they had received sufficient information regarding the 
disease and disease activity parameters.
In line with other studies, the findings in our study 
showed the extent to which patient beliefs influenced treat-
ment adherence – this has been widely reported in other 
chronic conditions, including asthma, cardiac disease, renal 
failure, cancer, and human immunodeficiency virus.14,15,26 
The NCF and SRM work suggests that a patient’s adherence 
decisions are a result of the balance between their perceived 
need for the medication (necessity) and their concerns 
regarding its use. We were able to explore how patients 
with RA balanced these to make decisions about DMARDs. 
Patients in our study who adhered well recognized the 
necessity of DMARD therapy, but some low-adhering South 
Asian patients clearly had doubts about their personal need 
for treatment. Studies on DMARD adherence, as well as 
studies on other conditions have also shown similar impor-
tance of medication beliefs.27–29 In our study, nonadherence 
in RA, therefore, was affected by individuals’ views about 
perceived illness.
Due to symptoms being episodic, the low-adhering 
patients tended to view their RA as being short term and 
nonserious. This was particularly evident in the South Asian 
patients. Similarly, a study conducted in India also found 
that South Asian patients did not regard RA as a serious 
condition and had negative beliefs about RA treatments.30 
Similar concepts have been reported among South Asian 
patients with other chronic conditions.31–34 In our study, 
South Asian patients with RA suggested that awareness 
of RA within their community and of the medication used 
for its management had an influence on their adherence to 
DMARDs. Lack of knowledge of RA and delays in initiat-
ing treatment have been reported in our previous work.35,36 
Furthermore, a study conducted in India30 reported that South 
Asian patients with RA were more familiar with traditional 
remedies than Western medicines, and were found to be using 
these remedies alongside Western medicines. Similarly, our 
study has also found that some patients viewed traditional 
remedies favorably and felt that these could help to improve 
their RA symptoms.
Our study has identified potentially modifiable patient 
beliefs. Clinicians need to address patients’ perceptions of 
medication need and concerns early in the treatment course. 
The key messages from our data were that the need for 
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treatment and decisions to continue taking DMARDs were 
reinforced by receiving adequate information and exposure 
to visual representations of the disease process, particularly 
images of their own joints obtained by ultrasound or plain 
radiography. Evidence regarding improving patients’ experi-
ences or understanding of the disease by ultrasound scanning 
is not well documented in RA.37 To date, one pilot study of 
18 patients with RA has suggested that using ultrasound to 
illustrate the processes operating in their joints can reduce 
patients’ concerns about treatment.37 Furthermore, the study 
showed that using ultrasound scans as an educational tool 
helped to increase beliefs about the necessity of treatment. 
However, with its small sample size and short follow-up, 
the study was not designed to measure the effect of this 
intervention on medication adherence levels. Larger studies 
are required to investigate the role of ultrasound scanning in 
improving medication adherence in RA. The findings of our 
study suggested that apart from visualization of joints, the 
ability to view graphical plots of clinical parameters such as 
the disease activity score and levels of inflammatory markers 
may be helpful in improving patients’ understanding of the 
need for long-term therapy.
The utility of pictorial/visualization tools to engage 
patients in understanding their disease and its treatment 
and in reducing anxiety has been reported in other condi-
tions. For example, in relation to ovarian cancer, it has been 
shown that the use of ultrasound scanning of the ovaries 
reduced patients’ anxiety and improved their confidence 
and well-being.38 Furthermore, the use of a moving three-
dimensional heart in the context of explanation of future 
risks of heart disease had more impact on patients than did 
text-based information alone.39,40 The authors noted that the 
three-dimensional images of the heart increase patients’ 
common sense understanding of heart disease risk, causal 
beliefs, and control beliefs. Moreover, patients made more 
behavioral lifestyle changes, such as eating a healthy diet and 
taking up physical exercise, in response to such images.17 In 
a separate study40 that demonstrated change in behavior, the 
authors reported that an intervention, whose development 
was informed by components of the CSM, enhanced patients’ 
understanding of heart disease risk and had a motivational 
effect on patient engagement. Building similar interven-
tions in rheumatology might benefit patients from ethnic 
backgrounds such as those of South Asian origin who may 
need to be educated more about the differences between 
“curing” and “treating” RA with medicines and may also be 
of particular value in improving overall clinical outcomes 
in all patients.
This study had a number of limitations. Firstly, patients’ 
views about other medicines that they were taking were not 
explored. Data regarding patients’ views about medications 
such as antihypertensives might have provided insights 
regarding their relative views about different classes of 
drugs used to treat different conditions. The data from this 
study suggested that patients with RA expressed different 
views about conventional and biological DMARDs based on 
their experiences of the relative efficacy of these classes of 
medications. These views might have an effect on adherence; 
however, this aspect was not fully explored. The views of 
patients who refused to take part could have been different 
to those presented in this study. Despite these limitations, the 
strength of this study was that it captured views about medica-
tion adherence from adherent and nonadherent patients.
Conclusion
This study provides a deeper understanding of adherence to 
DMARDs in patients with RA. Improving adherence is likely 
to be facilitated by incorporating visual representations of 
the disease process, open discussion of disease parameters, 
and better explanations of the consequences of poorly con-
trolled RA into the consultation. A good relationship with 
health professionals may also promote patients’ adherence 
to DMARDs.
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